{"transactions":[{"id":946502,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":102.5,"underlying":"Common Stock","underlying_shares":2088},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946501,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946500,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":257,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.75,"underlying":"Common Stock","underlying_shares":257},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946499,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":380,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":31.5,"underlying":"Common Stock","underlying_shares":380},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946498,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":85.5,"underlying":"Common Stock","underlying_shares":146},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946497,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946496,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":106.25,"underlying":"Common Stock","underlying_shares":138},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946495,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946494,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":416,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":416},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946493,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":372.5,"underlying":"Common Stock","underlying_shares":1002},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946492,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":101,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":527.25,"underlying":"Common Stock","underlying_shares":101},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946491,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":572.5,"underlying":"Common Stock","underlying_shares":368},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946490,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":134,"underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946489,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946488,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":400,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":306.75,"underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946487,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":142,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":434.75,"underlying":"Common Stock","underlying_shares":142},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946486,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":9.0775,"underlying":"Common Stock","underlying_shares":2460},"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":946485,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:55:45.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":578,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001389","document":"tm261736-12_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001389/tm261736-12_4seq1.xml","form_type":"4"}},{"id":1111479,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:57:22.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":61500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":61500,"derivative":{"exercise_price":0.36,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61500},"source":{"system":"sec-edgar","filing":"0001104659-25-059428","document":"tm2517941-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925059428/tm2517941-3_4seq1.xml","form_type":"4"}},{"id":1465672,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-07-01T17:03:24.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.13 based on an exchange rate of U.S.$ 1.263714 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":660000,"derivative":{"exercise_price":0.16,"exercise_date":"2025-07-01","expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001104659-24-076894","document":"tm2418639-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1299171/000110465924076894/tm2418639-5_4seq1.xml","form_type":"4"}},{"id":1481972,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:52:46.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.26,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-24-070896","document":"tm2417031-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924070896/tm2417031-4_4seq1.xml","form_type":"4"}},{"id":1677689,"issuer":{"id":9824,"kind":"organization","name":"Adaptimmune Therapeutics PLC"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to purchase Ordinary Shares","published_at":"2024-01-17T17:03:04.000Z","date":"2024-01-15","kind":"grant","planned":false,"acquired":true,"shares":81906,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price was converted from GBP0.11 based on an exchange rate of U.S.$ 1.274570 to GBP1.00. The actual exercise price will be the pounds sterling amount."}],"balance_after":81906,"derivative":{"exercise_price":0.14,"exercise_date":"2025-01-15","expiration_date":"2034-01-15","underlying":"Ordinary Shares","underlying_shares":81906},"source":{"system":"sec-edgar","filing":"0001104659-24-004530","document":"tm243270-11_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1299171/000110465924004530/tm243270-11_4seq1.xml","form_type":"4"}},{"id":1687624,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-04T21:14:49.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":6447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash.  The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $12,250 for the quarter ended December 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":6447,"derivative":{"exercise_price":2.27,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":6447},"source":{"system":"sec-edgar","filing":"0001104659-24-001361","document":"tm241899-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924001361/tm241899-3_4seq1.xml","form_type":"4"}},{"id":1765222,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-10-04T20:29:43.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":9523,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $10,000 for the quarter ended September 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":9523,"derivative":{"exercise_price":1.26,"expiration_date":"2033-10-01","underlying":"Common Stock","underlying_shares":9523},"source":{"system":"sec-edgar","filing":"0001104659-23-106837","document":"tm2327613d3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923106837/tm2327613d3_4seq1.xml","form_type":"4"}},{"id":1824908,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-21T21:00:36.000Z","date":"2023-07-19","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.72,"expiration_date":"2033-07-18","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-23-043123","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919123043123/doc4.xml","form_type":"4"}},{"id":1833758,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-07-06T20:21:20.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":3654,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $10,000 for the quarter ended June 30, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant."}],"balance_after":3654,"derivative":{"exercise_price":3.42,"expiration_date":"2033-07-02","underlying":"Common Stock","underlying_shares":3654},"source":{"system":"sec-edgar","filing":"0001104659-23-078751","document":"tm2320657-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923078751/tm2320657-4_4seq1.xml","form_type":"4"}},{"id":1858673,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:17:47.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070363","document":"tm2318463-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070363/tm2318463-5_4seq1.xml","form_type":"4"}},{"id":1858672,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:17:47.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":14467,"source":{"system":"sec-edgar","filing":"0001104659-23-070363","document":"tm2318463-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070363/tm2318463-5_4seq1.xml","form_type":"4"}},{"id":1924928,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-04-05T21:15:43.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":3451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This stock option was granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of stock options rather than cash. The options were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $11,250 for the quarter ended March 31, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Fully vested as of the date of grant"}],"balance_after":3451,"derivative":{"exercise_price":4.25,"expiration_date":"2033-04-02","underlying":"Common Stock","underlying_shares":3451},"source":{"system":"sec-edgar","filing":"0001104659-23-042247","document":"tm2311858-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923042247/tm2311858-5_4seq1.xml","form_type":"4"}},{"id":2224262,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T21:34:15.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.54,"expiration_date":"2032-06-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-038725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000120919122038725/doc4.xml","form_type":"4"}},{"id":2235783,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:17:13.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070136","document":"tm2218135-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070136/tm2218135-1_4seq1.xml","form_type":"4"}},{"id":2443721,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:04:52.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":10416,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":10416},"source":{"system":"sec-edgar","filing":"0001104659-22-001557","document":"tm221771-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001557/tm221771-4_4seq1.xml","form_type":"4"}},{"id":2668159,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:02:46.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":25050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25050,"derivative":{"exercise_price":14.9,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":25050},"source":{"system":"sec-edgar","filing":"0001104659-21-081608","document":"tm2119714-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921081608/tm2119714-3_4seq1.xml","form_type":"4"}},{"id":2902202,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-21T00:02:11.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":2547,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021."}],"balance_after":2547,"derivative":{"exercise_price":21.09,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":2547},"source":{"system":"sec-edgar","filing":"0001104659-21-005943","document":"tm211948-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921005943/tm211948-3_4seq1.xml","form_type":"4"}},{"id":3097497,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-30T00:11:13.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2021 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":9200,"derivative":{"exercise_price":22.9,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001104659-20-078227","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920078227/a4.xml","form_type":"4"}},{"id":3322776,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T21:38:17.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":11264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020."}],"balance_after":11264,"derivative":{"exercise_price":5.36,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":11264},"source":{"system":"sec-edgar","filing":"0001104659-20-000913","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920000913/a4.xml","form_type":"4"}},{"id":3494087,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T20:35:30.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2020 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25000,"derivative":{"exercise_price":4.31,"expiration_date":"2029-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-19-034798","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919034798/a4.xml","form_type":"4"}},{"id":3495842,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2019-06-10T19:07:50.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control."}],"balance_after":35000,"derivative":{"exercise_price":7.99,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-19-035745","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000120919119035745/doc4.xml","form_type":"4"}},{"id":3785912,"issuer":{"id":4104,"kind":"organization","name":"Arcus Biosciences, Inc."},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-22T23:24:25.000Z","date":"2018-10-19","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is exercisable in 36 equal monthly installments after October 19, 2018, subject to the Reporting Person's continued service to the Company."}],"balance_after":35000,"derivative":{"exercise_price":11.79,"expiration_date":"2028-10-18","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-18-027179","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724521/000089924318027179/doc4.xml","form_type":"4"}},{"id":3809789,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-09-21T20:01:14.000Z","date":"2018-09-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2019 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":10000,"derivative":{"exercise_price":12.27,"expiration_date":"2028-09-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001104659-18-058011","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465918058011/a4.xml","form_type":"4"}},{"id":4107377,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":69987,"kind":"person","name":"Hege Kristen","position":1,"cik":"0001299171","reported_name":"Hege Kristen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-01-04T21:03:52.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":3560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2018."}],"balance_after":3560,"derivative":{"exercise_price":17.39,"expiration_date":"2028-01-02","underlying":"Common Stock","underlying_shares":3560},"source":{"system":"sec-edgar","filing":"0001104659-18-000769","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465918000769/a4.xml","form_type":"4"}}]}